23 July 2020

Reig Jofre presents the second quarter 2020 results

23 July 2020

Reig Jofre releases first half 2020 results note

23 July 2020

Resolutions of the General Shareholders’ Meeting

21 July 2020

Transactions within the share buy-back program

16 July 2020

Reig Jofre contributes its know-how in the development of biological vaccines to the innovative consortium of Vaxdyn

2 July 2020

Start of the first temporary share buyback program

1 July 2020

Termination of the liquidity contract

18 June 2020

Reschedule of 1H 2020 results

17 June 2020

Reig Jofre convenes its 2020 General Shareholders´ Meeting

7 May 2020

Reig Jofre closes the first quarter of 2020 with a growth of 26% in sales

6 May 2020

Reig Jofre begins a clinical study to reduce the incidence of COVID-19 and its severity in the event of infection

23 March 2020

General Shareholders’ Meeting postponed

10 March 2020

Reig Jofre launches a new hospital medicine in Spain and Europe for the treatment of narcolepsy

28 February 2020

Reig Jofre reaches € 200 million in revenue and closes 2019 with a growth of 11% in sales and 20% in EBITDA

5 February 2020

The use of chondroprotectors (SYSADOA) would enable the NHS to avoid around 20,000 adverse effects per year, with an economic saving of more than 40 million Euros over three years

27 January 2020

Reig Jofre reaches a new milestone: 5 million vials of injectable Remifentanil marketed in Japan

22 January 2020

Publication schedule for 2020 results

20 January 2020

Forté Pharma, Reig Jofre’s line of nutritional supplements, launches EXPERT LIFT’ FILLER

8 January 2020

Begining of the liquidity contract

7 January 2020

End of the share buy-back program